Hybio Pharmaceutical Co., Ltd. (300199.SZ) — Stock Score Summary

Hybio Pharmaceutical Co., Ltd. (300199.SZ) has a MoatMap StockRank of 34/100 based on Quality (50/100), Value (13/100), and Momentum (58/100) factor scores. The current signal is SELL. Hybio Pharmaceutical lacks the scale, regulatory validation, and high-utilization profile required to benefit from the CDMO pricing power cycle. With a weak value score and highly speculative earnings profile, it does not meet our quality compounding criteria.

Hybio Pharmaceutical Co., Ltd. is a leading Chinese biopharmaceutical company specializing in the research, development, and manufacturing of peptide APIs and formulations. The company's product portfolio includes peptide drugs for cardiovascular, metabolic, and obstetric indications, alongside a growing contract development and manufacturing (CDMO) business. Its competitive moat is anchored by its advanced, large-scale peptide synthesis platforms and a strong portfolio of international patents and regulatory approvals.

Key Financial Metrics

Price$3.07
Market Cap$3.0B
P/E (TTM)214.90
P/E (Forward)71.63
Price/Book25.58
Return on Equity12.9%
Return on Invested Capital11.8%
Debt/Equity258.80
Gross Margin57.7%
Operating Margin38.0%
Revenue Growth-3.5%
Free Cash Flow$-3M

Hybio Pharmaceutical Co., Ltd. operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (China).

Frequently Asked Questions

What is Hybio Pharmaceutical Co., Ltd.’s (300199.SZ) StockRank?
MoatMap’s StockRank for Hybio Pharmaceutical Co., Ltd. (300199.SZ) is 34/100, with a Sell signal. It is a composite of Quality (50), Value (13), and Momentum (58) factor ranks across MoatMap’s 19,000+ stock universe.
Does Hybio Pharmaceutical Co., Ltd. have an economic moat?
Hybio Pharmaceutical Co., Ltd. (300199.SZ) has a Quality factor score of 50/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Hybio Pharmaceutical Co., Ltd. a buy, hold, or sell?
MoatMap’s current signal for Hybio Pharmaceutical Co., Ltd. (300199.SZ) is Sell, based on a StockRank of 34/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Hybio Pharmaceutical Co., Ltd. in?
Hybio Pharmaceutical Co., Ltd. (300199.SZ) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (China).
Browse all ranked stocks300199.SZ deep dive reportAI ChampionsHow we score stocksSense-check another stock